The value of listings hit a new quarterly high courtesy of Guardant and Axonics.
The buoyant biopharma IPO scene set several new records in 2018, a notable achievement given the stock market turmoil of the fourth quarter.
After Monday’s celebrations the sector gets down to discussing the difficult business of actually selling and making money from drugs.
If the recent performance of biotech stocks prompted you to pull down the shutters until the New Year celebrations subsided here’s what you might have missed.
Vantage publishes its annual look ahead to 2019, examining the trends and issues that will shape biopharma in the coming year.
Moderna’s upsized IPO is the biggest-ever for a pre-commercial biotech. But its share price has fallen in early trade on its first day.
The buttoned-up biotech, recently valued at $7bn, has finally unveiled plans to go public. But investor appetite for new issues has taken a knock. Does Moderna’s move…
Guardant Health says its tests have a market opportunity of $35bn, and now has to justify investors’ faith.
As Allogene moves to follow Autolus onto the public markets, its IPO document could give hope that Cellectis’s allogeneic assets will at long last make meaningful…